Offspring Biosciences
Contract research organization providing human tissue–centric translational pathology services for antibody and drug development. Integrates pathology-verified human disease tissue cohorts, multiplex spatial assays, and AI-driven quantitative image analysis to generate spatially resolved, decision-grade evidence for target validation, antibody selection, safety screening, and clinical biomarker development.
Industries
Nr. of Employees
small (1-50)
Offspring Biosciences
Södertälje, Stockholm, Sweden
Services
Map and quantify target mRNA and protein expression across indication-relevant human disease and control cohorts to confirm disease relevance and spatial distribution.
High-volume screening and iterative make-test cycles to identify antibody clones with selective engagement, affinity, and robustness in fixed human disease tissue; includes competitive benchmarking.
Visualization and quantification of drug-target engagement and downstream pharmacodynamic biomarkers in human and preclinical tissues using proximity assays, multiplex staining, autoradiography, and AI quantification to support proof-of-mechanism and dose selection.
Rapid, ISO-aligned multi-organ screening to detect off-target binding across critical human organs as a front-loaded safety filter prior to full GLP TCR studies.
Responder population profiling, clinical assay characterization, and transition support to regulated clinical testing environments (CAP/CLIA) via strategic partners; includes multiplex assays for trial biopsies and assay handover paths.
Ligand binding studies and autoradiography in pathology-verified human tissue to validate PET tracer affinity and specificity prior to clinical imaging investment.
Map and quantify target mRNA and protein expression across indication-relevant human disease and control cohorts to confirm disease relevance and spatial distribution.
High-volume screening and iterative make-test cycles to identify antibody clones with selective engagement, affinity, and robustness in fixed human disease tissue; includes competitive benchmarking.
Visualization and quantification of drug-target engagement and downstream pharmacodynamic biomarkers in human and preclinical tissues using proximity assays, multiplex staining, autoradiography, and AI quantification to support proof-of-mechanism and dose selection.
Rapid, ISO-aligned multi-organ screening to detect off-target binding across critical human organs as a front-loaded safety filter prior to full GLP TCR studies.
Responder population profiling, clinical assay characterization, and transition support to regulated clinical testing environments (CAP/CLIA) via strategic partners; includes multiplex assays for trial biopsies and assay handover paths.
Ligand binding studies and autoradiography in pathology-verified human tissue to validate PET tracer affinity and specificity prior to clinical imaging investment.
Expertise Areas
- Translational pathology using human disease tissue
- Antibody lead selection and optimization in tissue context
- Target validation and spatial biology
- Multiplexed tissue assay development
Key Technologies
- Tissue microarrays (TMA)
- Multiplex immunohistochemistry / immunofluorescence
- RNA in situ hybridization (RNAscope-style ISH)
- In situ proximity ligation assays (isPLA)
News & Updates
Case study describing tissue-first validation workflows that supported the selection and translational validation of an anti–alpha-synuclein antibody, including proximity assays, IHC, immunodepletion selectivity measurements, and AI quantification.
Technical white paper describing the platform architecture, tissue library specifications, and analytical capabilities for de-risking antibody development.
Blog post outlining a tissue-based translational framework that applies target relevance, drug engagement, mechanism, safety, and patient selection principles to reduce clinical attrition.
Provided human tissue–based target validation, specificity profiling and translational data that contributed to the clinical advancement of an anti–alpha-synuclein antibody into Phase 2a trials.
Case study describing tissue-first validation workflows that supported the selection and translational validation of an anti–alpha-synuclein antibody, including proximity assays, IHC, immunodepletion selectivity measurements, and AI quantification.
Technical white paper describing the platform architecture, tissue library specifications, and analytical capabilities for de-risking antibody development.
Blog post outlining a tissue-based translational framework that applies target relevance, drug engagement, mechanism, safety, and patient selection principles to reduce clinical attrition.
Provided human tissue–based target validation, specificity profiling and translational data that contributed to the clinical advancement of an anti–alpha-synuclein antibody into Phase 2a trials.